The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core.
BACKGROUND
This is a progress report of the Alzheimer's Disease Neuroimaging Initiative (ADNI) positron emission tomography (PET) Core.


METHODS
The Core has supervised the acquisition, quality control, and analysis of longitudinal [(18)F]fluorodeoxyglucose PET (FDG-PET) data in approximately half of the ADNI cohort. In an "add on" study, approximately 100 subjects also underwent scanning with [(11)C] Pittsburgh compound B PET for amyloid imaging. The Core developed quality control procedures and standardized image acquisition by developing an imaging protocol that has been widely adopted in academic and pharmaceutical industry studies. Data processing provides users with scans that have identical orientation and resolution characteristics despite acquisition on multiple scanner models. The Core labs have used many different approaches to characterize differences between subject groups (Alzheimer's disease, mild cognitive impairment, controls), to examine longitudinal change over time in glucose metabolism and amyloid deposition, and to assess the use of FDG-PET as a potential outcome measure in clinical trials.


RESULTS
ADNI data indicate that FDG-PET increases statistical power over traditional cognitive measures, might aid subject selection, and could substantially reduce the sample size in a clinical trial. Pittsburgh compound B PET data showed expected group differences, and identified subjects with significant annual increases in amyloid load across the subject groups. The next activities of the PET core in ADNI will entail developing standardized protocols for amyloid imaging using the [(18)F]-labeled amyloid imaging agent AV45, which can be delivered to virtually all ADNI sites.


CONCLUSIONS
ADNI has demonstrated the feasibility and utility of multicenter PET studies and is helping to clarify the role of biomarkers in the study of aging and dementia.
Jagust
William J
WJ
Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA. jagust@berkeley.edu
Bandy
Dan
D
Chen
Kewei
K
Foster
Norman L
NL
Landau
Susan M
SM
Mathis
Chester A
CA
Price
Julie C
JC
Reiman
Eric M
EM
Skovronsky
Daniel
D
Koeppe
Robert A
RA
D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000000981:diagnostic imaging*; D000682:Amyloid / Q000378:metabolism; D000814:Aniline Compounds; D001931:Brain Mapping; D015331:Cohort Studies; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D021621:Imaging, Three-Dimensional; D008297:Male; D049268:Positron-Emission Tomography / Q000379:methods*; D012189:Retrospective Studies; D013844:Thiazoles
C475519:2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole; D000682:Amyloid; D000814:Aniline Compounds; D013844:Thiazoles; D019788:Fluorodeoxyglucose F18
Arch Neurol. 2008 Nov;65(11):1509-17
19001171
J Consult Clin Psychol. 1991 Feb;59(1):12-9
2002127
Neuroimage. 2010 Jun;51(2):654-64
20202480
Brain. 2007 Oct;130(Pt 10):2616-35
17704526
J Nucl Med. 2009 Nov;50(11):1887-94
19837759
N Engl J Med. 1996 Mar 21;334(12):752-8
8592548
J Nucl Med. 1995 Jul;36(7):1238-48
7790950
Neurology. 2009 Oct 13;73(15):1193-9
19822868
JAMA. 1995 Mar 22-29;273(12):942-7
7884953
Neuroimage. 2009 Dec;48(4):668-81
19615450
Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):284-9
14688411
Neuroimage. 2009 May 1;45(4):1107-16
19349228
Neurobiol Aging. 2011 Jul;32(7):1207-18
19660834
Neuroimage. 2009 May 15;46(1):154-9
19457369
Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S29-36
18631997
Proc Natl Acad Sci U S A. 2000 May 23;97(11):6037-42
10811879
Brain. 2006 Nov;129(Pt 11):2856-66
16854944